View in EDS HTML Full Text PDF Full Text

Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.
Authors: Standing D; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Arnold L; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Dandawate P; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Ottemann B; Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas, USA., Snyder V; Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas, USA., Ponnurangam S; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Sayed A; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Subramaniam D; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Srinivasan P; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Choudhury S; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., New J; Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas, USA.; Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Kwatra D; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Ramamoorthy P; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Roy BC; Department of General Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Shadoin M; Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas, USA., Al-Rajabi R; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., O'Neil M; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Gunewardena S; Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas, USA., Ashcraft J; Department of General Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Umar S; Department of General Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Weir SJ; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.; Institute for Advancing Medical Innovation, University of Kansas Medical Center, Kansas City, Kansas, USA., Tawfik O; Department of Pathology, Saint Luke's Health System, Kansas City, Missouri, USA.; MAWD Pathology Group, Kansas City, Kansas, USA., Padhye SB; Department of Chemistry, Interdisciplinary Science and Technology Research Academy, University of Pune, Pune, India., Biersack B; Department of Chemistry, University of Bayreuth, Bayreuth, Germany., Anant S; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA., Thomas SM; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.; Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas, USA.; Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Source: Molecular carcinogenesis [Mol Carcinog] 2023 Feb; Vol. 62 (2), pp. 145-159. Date of Electronic Publication: 2022 Oct 11.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8811105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2744 (Electronic) Linking ISSN: 08991987 NLM ISO Abbreviation: Mol Carcinog Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1098-2744
DOI:10.1002/mc.23472